Preferential Selectivity of Inhibitors with Human Tau Protein Kinase Gsk3 Elucidates Their Potential Roles for Off-Target Alzheimer’s Therapy
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid beta peptides (A) and neurofibrillary tangles (NFTs). The abnormal phosphorylation of tau leads to the formation of NFTs produced by the action of tau kinases, resulting in the loss of...
Main Authors: | Jagadeesh Kumar Dasappa, H. G. Nagendra |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | International Journal of Alzheimer's Disease |
Online Access: | http://dx.doi.org/10.1155/2013/809386 |
Similar Items
-
GSK3β and Tau Protein in Alzheimer’s Disease and Epilepsy
by: Danira Toral-Rios, et al.
Published: (2020-03-01) -
GSK-3 and Tau: A Key Duet in Alzheimer’s Disease
by: Carmen Laura Sayas, et al.
Published: (2021-03-01) -
Heparin effect on tau phosphorylation by protein kinase FA/GSK- 3α
by: Shiah, Shine-Gwo, et al.
Published: (1994) -
A Mathematical Model of Tau Protein Hyperphosphorylation: The Effects of Kinase Inhibitors as a Theoretical Alzheimer's Disease Therapy
by: Blank, Patrick Neil
Published: (2015) -
Hsp90 Maintains the Stability and Function of the Tau Phosphorylating Kinase GSK3β
by: Da Ma, et al.
Published: (2007-01-01)